Implications of recent hypertension trials for the generalist physician: whom do we treat, and how?
Abstract The publication of the results of 2.75x100 the Swedish Trial in Old Patients with Hypertension-2 (STOP-2) and the termination of the doxazocin arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack (ALLHAT) study again raise the question of whether all antihypertensives deliver equal cardiovascular outcome benefit